Loading...
•
Mar 31, 2023
Amedisys Q1 2023 Earnings Report
Amedisys reported mixed Q1 2023 results with revenue increase but net income decrease, while adjusted EBITDA and EPS outperformed internal expectations. The company updated its 2023 guidance.
Key Takeaways
Amedisys reported a slight increase in net service revenue to $556.4 million, but net income decreased to $25.2 million. However, adjusted EBITDA and EPS exceeded internal expectations. The company updated its 2023 guidance, projecting adjusted net service revenue between $2.254 billion and $2.274 billion, adjusted EBITDA between $235 million and $245 million, and adjusted diluted EPS between $4.14 and $4.36.
Net service revenue increased to $556.4 million compared to $545.3 million in the prior year.
Net income attributable to Amedisys, Inc. decreased to $25.2 million from $31.7 million in the prior year.
Adjusted EBITDA was $57.8 million compared to $66.3 million in the prior year.
The company updated its 2023 guidance for adjusted net service revenue, adjusted EBITDA, and adjusted diluted earnings per share.
Amedisys
Amedisys
Forward Guidance
Amedisys updated its 2023 guidance, projecting adjusted net service revenue between $2.254 billion and $2.274 billion, adjusted EBITDA between $235 million and $245 million, and adjusted diluted EPS between $4.14 and $4.36. This guidance excludes the effects of any future acquisitions and potential share repurchases, if any are made, and excludes the impact of the Company's pending combination with Option Care Health.
Positive Outlook
- Adjusted net service revenue is anticipated to be in the range of $2.254 billion to $2.274 billion.
- Adjusted EBITDA is anticipated to be in the range of $235 million to $245 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $4.14 to $4.36 based on an estimated 32.8 million shares outstanding.
- Strong home health admissions.
- Hospice adjusted EBITDA margin improvement.
Challenges Ahead
- The guidance excludes the effects of any future acquisitions and potential share repurchases.
- The guidance excludes the impact of the Company's pending combination with Option Care Health.
- The home health, hospice and high acuity care industries are highly competitive.
- The industries are subject to intensive regulations.
- Trends are subject to numerous factors, risks, and uncertainties.